Observational, Retrospective Study to Evaluate Coagulation Changes and the Influence of Antithrombin III Treatment in Patients With Severe COVID-19 Infection

CompletedOBSERVATIONAL

Enrollment

300

Participants

Timeline

Start Date

October 19, 2020

Primary Completion Date

September 27, 2022

Study Completion Date

September 27, 2022

Conditions

Covid19

Interventions

DRUG

Antithrombin III

Trial Locations (6)

Octapharma Research Site, Vienna

Octapharma Research Site, Innsbruck

ECMO Centre Karolinska, Stockholm

Octapharma Research Site, Essen

Octapharma Research Site, Aachen

Octapharma Research Site, Strasbourg